X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/22/2866826/0/en/Sagimet-Biosciences-to-Host-Virtual-Investor-and-Analyst-Day-on-Inhibiting-Fatty-Acid-Synthase-FASN-to-Reduce-Liver-Fat-Inflammation-and-Fibrosis-in-MASH-on-May-3-2024.html
https://www.globenewswire.com/news-release/2024/03/27/2853583/0/en/Sagimet-Biosciences-Announces-Completion-of-Phase-1-Hepatic-Impairment-Study-with-FASN-Inhibitor-Denifanstat.html
https://www.globenewswire.com/news-release/2024/03/25/2851497/0/en/Sagimet-Biosciences-Announces-Appointment-of-Tim-Walbert-and-Paul-Hoelscher-to-its-Board-of-Directors.html
https://www.globenewswire.com/news-release/2024/03/25/2851458/0/en/Sagimet-Biosciences-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-Updates.html
https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-participate-two-upcoming-investor
https://www.globenewswire.com//news-release/2024/01/26/2817557/0/en/Sagimet-Biosciences-Announces-Pricing-of-Public-Offering-of-Series-A-Common-Stock.html
https://www.globenewswire.com//news-release/2024/01/23/2814584/0/en/Sagimet-Biosciences-Announces-Proposed-Public-Offering-of-Series-A-Common-Stock.html
https://www.fiercebiotech.com/biotech/sagimet-stock-doubles-phase-2b-nash-trial-hits-primary-goals
https://www.prnewswire.com/news-releases/gannexs-strategic-partner-sagimet-biosciences-announces-positive-topline-results-from-phase-2b-fascinate-2-clinical-trial-of-denifanstat-in-biopsy-confirmed-f2f3-nash-302041397.html
https://www.globenewswire.com//news-release/2023/12/04/2789953/0/en/Sagimet-Biosciences-to-Participate-in-the-First-Annual-Goldman-Sachs-Catalyst-Clinic.html
Market Place
Share 
